Adverum Biotechnologies Company Leadership
| ADVM Stock | USD 6.04 0.29 5.04% |
Adverum Biotechnologies' insiders are aggressively buying. The analysis of the overall insider sentiment regarding Adverum Biotechnologies suggests that most insiders are extremely bullish. Adverum Biotechnologies employs about 121 people. The company is managed by 18 executives with a total tenure of roughly 283 years, averaging almost 15.0 years of service per executive, having 6.72 employees per reported executive.
Adverum Biotechnologies' Insider Buying Vs Selling
100
Selling | Buying |
Latest Trades
| 2024-07-30 | Braden Michael Leonard | Acquired 85800 @ 7.15 | View | ||
| 2024-07-17 | Braden Michael Leonard | Acquired 135546 @ 7.75 | View | ||
| 2024-02-07 | James Paul Scopa | Acquired 10000 @ 13.5 | View |
Monitoring Adverum Biotechnologies' insider sentiment can offer insights into its future performance, as insiders often have access to more information about their company's operations, financial health, and upcoming initiatives than the general public. However, it's essential to note that insider trading is regulated by securities laws, and insiders are required to disclose their trades publicly to ensure transparency and prevent unfair advantages based on non-public information.
Adverum |
Adverum Biotechnologies' Workforce Through the Years
Please note that employee historical analysis has become an increasingly important factor for investors assessing the risk associated with Adverum Biotechnologies' future performance. Based on our forecasts, it is anticipated that Adverum will maintain a workforce of about 120 employees by December 2024.Adverum Biotechnologies Management Team Effectiveness
The company has return on total asset (ROA) of (0.2983) % which means that it has lost $0.2983 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.7626) %, meaning that it created substantial loss on money invested by shareholders. Adverum Biotechnologies' management efficiency ratios could be used to measure how well Adverum Biotechnologies manages its routine affairs as well as how well it operates its assets and liabilities. As of the 24th of November 2024, Return On Tangible Assets is likely to drop to -0.71. In addition to that, Return On Capital Employed is likely to grow to -0.79. At this time, Adverum Biotechnologies' Total Assets are very stable compared to the past year. As of the 24th of November 2024, Non Currrent Assets Other is likely to grow to about 1.3 M, while Other Current Assets are likely to drop about 4.4 M.As of the 24th of November 2024, Common Stock Shares Outstanding is likely to grow to about 18.4 M, while Net Loss is likely to drop (146 M).
Adverum Biotechnologies Workforce Comparison
Adverum Biotechnologies is rated third in number of employees category among its peers. The total workforce of Health Care industry is presently estimated at about 620. Adverum Biotechnologies retains roughly 121 in number of employees claiming about 20% of equities under Health Care industry.
Adverum Biotechnologies Insider Trading History
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Adverum Biotechnologies insiders, such as employees or executives, is commonly permitted as long as it does not rely on Adverum Biotechnologies' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, Adverum Biotechnologies insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
| Buy/Sell Ratio | # Purchases Trades | # Sales Trades | Total Shares Purchased | Total Shares Sold | |
|---|---|---|---|---|---|
| 2024-09-01 | 3.0 | 3 | 1 | 302,064 | 0.00 |
| 2024-06-01 | 1.8333 | 11 | 6 | 193,500 | 20,750 |
| 2023-12-01 | 4.0 | 4 | 1 | 610,000 | 0.00 |
| 2023-09-01 | 0.5 | 1 | 2 | 850,000 | 6,201 |
| 2023-03-01 | 1.6667 | 5 | 3 | 2,055,000 | 61,898 |
| 2022-09-01 | 2.0 | 4 | 2 | 1,654,771 | 54,387 |
| 2022-06-01 | 2.4286 | 17 | 7 | 699,425 | 365,538 |
| 2022-03-01 | 2.25 | 9 | 4 | 3,035,000 | 0.00 |
| 2021-12-01 | 2.0 | 4 | 2 | 450,000 | 50,000 |
| 2021-09-01 | 1.4 | 7 | 5 | 1,905,000 | 494,766 |
| 2021-06-01 | 2.25 | 9 | 4 | 692,500 | 518,750 |
| 2021-03-01 | 3.6667 | 11 | 3 | 1,563,600 | 12,533 |
| 2020-12-01 | 1.0 | 2 | 2 | 57,783 | 20,000 |
| 2020-09-01 | 1.5 | 3 | 2 | 20,384 | 10,000 |
| 2020-06-01 | 0.7931 | 23 | 29 | 1,656,933 | 292,906 |
| 2020-03-01 | 0.9444 | 17 | 18 | 1,357,916 | 352,590 |
| 2019-12-01 | 0.3333 | 1 | 3 | 400,000 | 80,000 |
| 2019-06-01 | 1.0 | 8 | 8 | 1,650,000 | 44,441 |
| 2019-03-01 | 1.0 | 3 | 3 | 1,105,000 | 31,427 |
| 2018-06-01 | 5.5 | 11 | 2 | 575,134 | 9,250 |
| 2018-03-01 | 2.3333 | 7 | 3 | 1,242,000 | 30,447 |
| 2017-09-01 | 2.0 | 2 | 1 | 117,000 | 5,479 |
| 2017-06-01 | 8.5 | 17 | 2 | 820,335 | 10,052 |
| 2017-03-01 | 3.2 | 16 | 5 | 1,604,598 | 134,793 |
| 2016-06-01 | 5.3333 | 16 | 3 | 3,677,444 | 70,000 |
| 2015-12-01 | 1.3333 | 4 | 3 | 916,383 | 97,000 |
| 2015-09-01 | 3.0 | 6 | 2 | 270,664 | 23,000 |
| 2015-06-01 | 0.4176 | 38 | 91 | 336,800 | 436,403 |
| 2014-09-01 | 1.0417 | 50 | 48 | 12,431,826 | 18,780,636 |
Adverum Biotechnologies Notable Stakeholders
An Adverum Biotechnologies stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Adverum Biotechnologies often face trade-offs trying to please all of them. Adverum Biotechnologies' stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Adverum Biotechnologies' stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
| Laurent Fischer | CEO President | Profile | |
| Linda MA | Principal CFO | Profile | |
| Anand Reddi | VP Engagement | Profile | |
| Jim Wang | Chief Officer | Profile | |
| Andrew Ramelmeier | Chief Officer | Profile | |
| Romuald Corbau | Chief Officer | Profile | |
| Kalliopi MD | Senior Development | Profile | |
| Michael Steel | Senior Quality | Profile | |
| Rabia MD | Chief Officer | Profile | |
| Brigit Riley | Chief Officer | Profile | |
| Setareh PharmD | Chief Officer | Profile | |
| John JD | Senior Counsel | Profile | |
| Dena House | Organizational Resources | Profile | |
| Heikki Jouttijarvi | Senior Operations | Profile | |
| Kishor JD | Chief Officer | Profile | |
| Nancy Pecota | Principal Officer | Profile | |
| Bill PharmD | Senior Operations | Profile | |
| Carla Fiankan | Senior Affairs | Profile |
About Adverum Biotechnologies Management Performance
The success or failure of an entity such as Adverum Biotechnologies often depends on how effective the management is. Adverum Biotechnologies management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Adverum management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Adverum management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.68) | (0.71) | |
| Return On Capital Employed | (0.84) | (0.79) | |
| Return On Assets | (0.68) | (0.71) | |
| Return On Equity | (1.40) | (1.33) |
Adverum Biotechnologies Workforce Analysis
Traditionally, organizations such as Adverum Biotechnologies use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Adverum Biotechnologies within its industry.Adverum Biotechnologies Manpower Efficiency
Return on Adverum Biotechnologies Manpower
| Revenue Per Employee | 29.8K | |
| Revenue Per Executive | 200K | |
| Net Loss Per Employee | 968.3K | |
| Net Loss Per Executive | 6.5M | |
| Working Capital Per Employee | 643.5K | |
| Working Capital Per Executive | 4.3M |
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Adverum Biotechnologies. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in real. To learn how to invest in Adverum Stock, please use our How to Invest in Adverum Biotechnologies guide.You can also try the Share Portfolio module to track or share privately all of your investments from the convenience of any device.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Adverum Biotechnologies. If investors know Adverum will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Adverum Biotechnologies listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (5.95) | Revenue Per Share 0.059 | Quarterly Revenue Growth (0.70) | Return On Assets (0.30) | Return On Equity (0.76) |
The market value of Adverum Biotechnologies is measured differently than its book value, which is the value of Adverum that is recorded on the company's balance sheet. Investors also form their own opinion of Adverum Biotechnologies' value that differs from its market value or its book value, called intrinsic value, which is Adverum Biotechnologies' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Adverum Biotechnologies' market value can be influenced by many factors that don't directly affect Adverum Biotechnologies' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Adverum Biotechnologies' value and its price as these two are different measures arrived at by different means. Investors typically determine if Adverum Biotechnologies is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Adverum Biotechnologies' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.